Consultancy In Topical And Transdermal Drug Delivery


  • Proven management, communication, influencing and presentation skills.
  • Track record of product related innovation.
  • Extensive network of contacts within industry and academia.
  • Excellent knowledge of relevant scientific literature and opinion.
  • Practical and in-depth experience of interaction with regulatory agencies.
  • Key development team member at Acrux for Axiron® (a novel transdermal testosterone product) approved by the US FDA in November 2010 and licensed to Eli Lilly in a deal worth in e
    xcess of US$300 million. Axiron® was launched in the US by Eli Lilly in 2011.
  • Key member of the regulatory team at Acrux for the approval of Ellavie™ (a novel transdermal estradiol spray) by the Medical Products Agency (MPA) in Sweden in May 2011 and SwissMedic in Switzerland in Jan 2012.
  • Member of the Skills and Public Support Working Group of the Biotechnology Strategic Development Plan for Victorian Government (2006-2009).
  • Initiator and champion of a development program that subsequently took Sancuso® granisteron transdermal patch to the US market in 2008. Sancuso was named in the top ten medical innovations of 2008 by Time magazine and was approved in Europe in April 2012.
  • Co-editor of the book “Transdermal and Topical Drug Delivery – Principles and Practice” published by John Wiley & Sons in January 2012.
  • Speaker at FDA CVM (Centre for Veterinary Medicine) session on transdermal technology.
  • Extensive publication record.
  • Several transdermal patents filed and granted.
  • Numerous podium and poster presentations at international conferences.
  • Session chair at international conferences.
  • Member of the scientific advisory board of the international conference, Perspectives on Percutaneous Penetration.